{
    "Trade/Device Name(s)": [
        "Simplexa C. difficile Direct",
        "Simplexa C. difficile Positive Control Pack"
    ],
    "Submitter Information": "Focus Diagnostics, Inc. DBA DiaSorin Molecular LLC",
    "510(k) Number": "K163085",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130470"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "OZN"
    ],
    "Summary Letter Date": "January 12, 2017",
    "Summary Letter Received Date": "January 17, 2017",
    "Submission Date": "February 10, 2017",
    "Regulation Number(s)": [
        "21 CFR 866.3130"
    ],
    "Regulation Name(s)": [
        "Clostridium difficile toxin gene amplification assay"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "genetic molecular"
    ],
    "Analyte(s)": [
        "Clostridium difficile toxin B gene (tcdB) DNA"
    ],
    "Specimen Type(s)": [
        "Liquid stool",
        "Unformed stool"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Integrated Cycler"
    ],
    "Method(s)/Technology(ies)": [
        "Real-time PCR",
        "Direct amplification"
    ],
    "Methodologies": [
        "Qualitative nucleic acid amplification",
        "Real-time PCR"
    ],
    "Submission Type(s)": [
        "Assay",
        "Control",
        "System",
        "Accessory"
    ],
    "Document Summary": "FDA 510(k) summary for Simplexa C. difficile Direct assay and Positive Control Pack for qualitative detection of C. difficile toxin B gene via real-time PCR in stool specimens",
    "Indications for Use Summary": "Aids in the detection of Clostridium difficile toxin B gene (tcdB) in liquid or unformed stool samples from individuals suspected of infection, using the Integrated Cycler instrument; Positive Control Pack is intended as an assay control.",
    "fda_folder": "Microbiology"
}